文献速递免疫规划妇幼与学校卫生

孕期接种破伤风、白喉和无细胞百日咳疫苗与婴儿急性呼吸道感染风险降低相关

Tetanus, diphtheria, and acellular pertussis vaccination during pregnancy and reduced risk of infant acute respiratory infections.
PubMed 文献 · Vaccine · 2017-09-12

这项回顾性队列研究纳入2006至2013年国防部出生与婴儿健康登记处中99,434名现役军人女性所生婴儿,评估孕期接种Tdap疫苗与婴儿2月龄内急性呼吸道感染的关联。孕期接种Tdap者婴儿2月龄内急性呼吸道感染风险降低9%(RR 0.91,95%CI 0.84-0.99),孕27至36周接种者风险降低17%(RR 0.83,95%CI 0.74-0.93)。作者认为研究结果强烈支持现行ACIP指南推荐每次妊娠晚期接种Tdap。

要点

  • 孕期接种Tdap疫苗与婴儿2月龄内急性呼吸道感染风险降低9%相关(RR 0.91,95%CI 0.84-0.99)。
  • 孕27至36周接种Tdap者婴儿急性呼吸道感染风险降低17%(RR 0.83,95%CI 0.74-0.93)。
  • 作者认为研究结果强烈支持ACIP指南推荐每次妊娠晚期接种Tdap。

核心结论

  • 孕期27至36周接种Tdap疫苗与婴儿出生后2月龄内急性呼吸道感染风险降低相关,且无论孕前是否接种过Tdap。
  • 作者认为研究结果强烈支持现行ACIP指南推荐每次妊娠晚期接种Tdap疫苗。

研究设计与样本

  • 回顾性队列研究,纳入2006年至2013年国防部出生与婴儿健康登记处中现役军人女性所生的99,434名婴儿。
  • 采用多变量对数二项回归计算孕期接种Tdap与婴儿2月龄内急性呼吸道感染关联的相对风险(RR)及95%置信区间(CI)。

主要发现

  • 孕期接种Tdap者较未接种者,婴儿2月龄内急性呼吸道感染诊断风险降低9%(RR 0.91,95%CI 0.84-0.99)。
  • 孕27至36周接种Tdap者较未接种者,婴儿急性呼吸道感染风险降低17%(RR 0.83,95%CI 0.74-0.93)。

关键数值与推荐

  • ACIP推荐孕妇在孕27至36周接种Tdap疫苗。
  • 孕期接种Tdap者婴儿2月龄内急性呼吸道感染风险RR 0.91(95%CI 0.84-0.99)。
  • 孕27至36周接种Tdap者婴儿急性呼吸道感染风险RR 0.83(95%CI 0.74-0.93)。
  • 孕前及孕27至36周均接种者较仅孕前接种者婴儿急性呼吸道感染风险RR 0.85(95%CI 0.74-0.98)。

临床怎么用

  • 作者认为研究结果强烈支持现行ACIP指南推荐每次妊娠晚期接种Tdap疫苗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To protect infants from pertussis infection, the Advisory Committee on Immunization Practices (ACIP) recommends women receive the tetanus toxoid, reduced diphtheria toxoid, acellular pertussis (Tdap) vaccine between 27 and 36weeks of pregnancy. Here, we assessed the association between timing of maternal Tdap vaccination during pregnancy and acute respiratory infection (ARI) in infants <2months of age. METHODS: This retrospective cohort study included 99,434 infants born to active duty military women in the Department of Defense Birth and Infant Health Registry from 2006 through 2013. Multivariable log-binomial regression was used to calculate relative risks (RRs) and 95% confidence intervals (CIs) for the association between maternal Tdap vaccination during pregnancy and infant ARI at <2months of age. RESULTS: Infants of mothers who received Tdap vaccination during pregnancy vs those who did not were 9% less likely to be diagnosed with an ARI at <2months of age (RR, 0.91; 95% CI, 0.84-0.99), and the risk was 17% lower if vaccination was received between 27 and 36weeks of pregnancy (RR, 0.83; 95% CI, 0.74-0.93). Similar results were observed when comparing mothers who received Tdap vaccination prior to pregnancy in addition to Tdap vaccination between 27 and 36weeks of pregnancy versus mothers who only received vaccination prior to pregnancy (RR, 0.85; 95% CI, 0.74-0.98). CONCLUSIONS: Maternal Tdap vaccination between 27 and 36weeks of pregnancy was consistently protective against infant ARI in the first 2months of life vs no vaccination during pregnancy, regardless of Tdap vaccination prior to pregnancy. Our findings strongly support current ACIP guidelines recommending Tdap vaccination in late pregnancy for every pregnancy.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Khodr ZG, Bukowinski AT, Gumbs GR, et al. Tetanus, diphtheria, and acellular pertussis vaccination during pregnancy and reduced risk of infant acute respiratory infections. Vaccine. 2017. PMID: 28916245. doi:10.1016/j.vaccine.2017.08.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。